Prolong Pharmaceuticals

Prolong Pharmaceuticals focuses on developing innovative biopharmaceuticals that address complex diseases, particularly in Central Nervous System, Hematology, and Respiratory Disorders, striving to meet unmet medical needs. Founded in 2002 in South Plainfield, US, Prolong Pharmaceuticals specializes in developing biopharmaceutical products. The company raised USD 30 mn in funding on October 14, 2010. The CEO is Abe Abuchowski, who has a history of founding and managing biotech ventures, although specific details of previous companies are not provided.

Prolong Pharmaceuticals specializes in developing innovative biopharmaceutical products aimed at addressing complex diseases and unmet medical needs, particularly in the fields of Central Nervous System (CNS), Hematology, and Respiratory Disorders. The company’s flagship product, PP-007 (Sanguinate®), is a PEGylated multifunctional gas transfer agent designed to restore homeostasis by delivering oxygen to hypoxic tissues while providing carbon monoxide to enhance perfusion and reduce inflammation. Prolong’s PEGylation technology has been proven in various FDA-approved treatments and is applied in novel ways to meet the urgent medical needs of patients suffering from conditions such as Stroke, Sickle Cell Disease, and Cystic Fibrosis. The company’s products are primarily targeted at healthcare providers and hospitals across North America, Europe, and select markets in Asia, focusing on regions with high incidences of the targeted diseases.

Prolong Pharmaceuticals operates through a structure that emphasizes partnerships with healthcare organizations and participation in clinical trials, enabling the advancement of its pipeline of therapeutic candidates. Revenue generation is anticipated through collaborations with hospitals and healthcare institutions that utilize its flagship product, PP-007 (Sanguinate®), during treatment procedures. The company engages in direct sales and potential contract agreements with healthcare providers to facilitate access to its innovative therapies. Pricing plans and transaction structures are tailored to the pharmaceutical market, ensuring accessibility for patients while maintaining compliance with regulatory standards.

As Prolong progresses through clinical trials and FDA approvals, the revenue model is expected to evolve, focusing on establishing long-term contracts and strategic partnerships within the biopharma industry. Prolong Pharmaceuticals plans to leverage the USD 30 mn raised in October 2010 to advance the development of upcoming products and enhance its market reach. The company is focusing on expanding into additional markets in Europe and Asia by 2025. The funding is expected to support clinical trials for new therapies, particularly those aimed at addressing the needs of patients with CNS disorders and other critical conditions.